ORNOPROSTIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H38O6
Molecular Weight	410.5442
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(=O)OC

InChI

InChIKey=BBRBUTFBTUFFBU-LHACABTQSA-N

InChI=1S/C23H38O6/c1-4-5-8-16(2)13-18(25)11-12-19-20(22(27)15-21(19)26)14-17(24)9-6-7-10-23(28)29-3/h11-12,16,18-21,25-26H,4-10,13-15H2,1-3H3/b12-11+/t16-,18+,19+,20+,21+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://pharmrev.aspetjournals.org/content/63/3/471.full
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01869

Ornoprostil is a methyl derivative of PGE1 with anti-ulcreative properties developed in Japan. It is a prostaglandin E1 receptor agonist.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cell growth 21 Target ID: GO:0016049 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1653751	Inhibitor 8504
Prostanoid EP1 receptor 14 Target ID: CHEMBL1811 Sources: http://www.genome.jp/dbget-bin/www_bget?D01869	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Peptic ulcer 72 Sources: http://drugs-about.com/drugs-r/rowok.html	Curative		Approved 8583	Rowok Approved Use Ornoprostil is used for treatment of peptic ulcers

Doses

Dose	Population	Adverse events
5 ug single, oral Studied dose Dose: 5 ug Route: oral Route: single Dose: 5 ug Sources: https://pubmed.ncbi.nlm.nih.gov/1940194/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1940194/	Sources: https://pubmed.ncbi.nlm.nih.gov/1940194/

PubMed

Title	Date	PubMed
[Effects of NSAIDs and PGE1 analogue on the permeability of human small intestine].	1997-07	9277110
Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins.	1996-10	8888721
[Prostaglandins: synthetic and pharmacological studies and development].	1992-07	1432596
Effect of synthetic prostaglandin E1 analog (ornoprostil) on gastric emptying and pancreatic polypeptide release after solid-meal ingestion in man.	1991-01	1985004
Gastric cytoprotection by ornoprostil, a PGE1 analogue, in human subjects.	1991	1940194
Effects of TY-10957, a stable PGI2 derivative, on gastroduodenal lesions and secretory responses in the rat.	1990	2112498
Roles of endogenous leukotrienes and prostaglandins in the healing of gastric ulcers induced by acetic acid in rats.	1989	2556789
[Effect of OU-1308 on uterine motility in pregnant rats and monkeys].	1987-09	3480845

Patents

Sample Use Guides

In Vivo Use Guide

Rats: 50 ug/kg/day, orally

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

ORNOPROSTIL

Official Name

English

RONOK

Preferred Name

English

ORNOPROSTIL [MI]

Common Name

English

ORNOPROSTIL [JAN]

Common Name

English

ornoprostil [INN]

Common Name

English

ORNOPROSTIL [MART.]

Common Name

English

METHYL (-)-(1R,2R,3R)-3-HYDROXY-2-((E)-(3S,5S)-3-HYDROXY-5-METHYL-1-NONENYL)-.EPSILON.,5-DIOXOCYCLOPENTANEHEPTANOATE

Systematic Name

English

Ornoprostil [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C78568